United Therapeutics Corporation announced record financial results for the full year and fourth quarter ended December 31, 2024. Full year 2024 revenues reached $2.88 billion, marking a 24% increase over 2023, while fourth quarter 2024 total revenues grew 20% year-over-year to $735.9 million.
Net income for the fourth quarter was $301.3 million, and diluted earnings per share stood at $6.19. The company's treprostinil franchise continued its strong performance, with total Tyvaso revenues growing 19% to $415.9 million in Q4 2024, driven by Tyvaso DPI's uptake in pulmonary hypertension associated with interstitial lung disease.
Remodulin, Orenitram, and Unituxin also showed robust growth in the fourth quarter, with revenues increasing 17% to $134.5 million, 28% to $107.8 million, and 25% to $67.5 million, respectively. The company also reported an accrued liability of $71.1 million related to ongoing litigation with Sandoz Inc. as of December 31, 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.